The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 5, Pages 1143
Publisher
MDPI AG
Online
2022-02-23
DOI
10.3390/cancers14051143
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2021) Qiang Wu et al. Frontiers in Oncology
- RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
- (2021) Kazuhiko Nakagawa et al. CLINICAL CANCER RESEARCH
- TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib
- (2021) Ruofei Yu et al. Translational Oncology
- Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
- (2021) Paola Ulivi et al. Biomedicines
- Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
- (2021) Si-Yang Liu et al. Nature Communications
- Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
- (2021) Damien Reita et al. Cancers
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
- (2020) Julia Roeper et al. Oncotarget
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
- (2020) Kang Qin et al. BMC CANCER
- Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer
- (2020) Jiyun Lee et al. CANCER
- Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
- (2020) Matteo Canale et al. Journal of Clinical Medicine
- Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma
- (2020) Feng Wang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
- (2020) Andrew J. Piper-Vallillo et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2020) Tony S. Mok et al. DRUGS
- Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
- (2020) N. Yamamoto et al. LUNG CANCER
- Predictive and Prognostic Potential of TP53 in Patients With Advanced Non–Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901)
- (2020) Xiang-Meng Li et al. Clinical Lung Cancer
- Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
- (2019) Anna-Lena Volckmar et al. INTERNATIONAL JOURNAL OF CANCER
- Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11
- (2019) Linnéa La Fleur et al. LUNG CANCER
- The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
- (2019) Anna Rachiglio et al. Cancers
- The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis
- (2019) Rui Zhang et al. POSTGRADUATE MEDICINE
- The multiple mechanisms that regulate p53 activity and cell fate
- (2019) Antonina Hafner et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling
- (2019) Yize Zhang et al. Cancer Cell International
- Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
- (2019) Michael Offin et al. Journal of Thoracic Oncology
- Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
- (2019) Yutao Liu et al. Oncology Letters
- Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
- (2019) Helei Hou et al. Cancer Management and Research
- Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
- (2019) Peter T Harrison et al. SEMINARS IN CANCER BIOLOGY
- Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer
- (2019) Weiwei Hong et al. Oncology Letters
- Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
- (2019) Ana C.Z. Gelatti et al. LUNG CANCER
- Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
- (2019) Jang Ho Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib
- (2019) Wenfeng Fang et al. Journal of Thoracic Oncology
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Sun Min Lim et al. CANCER TREATMENT REVIEWS
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
- (2018) Helena A. Yu et al. CLINICAL CANCER RESEARCH
- Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
- (2018) Dana Wai Yi Tsui et al. EMBO Molecular Medicine
- EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib
- (2018) Qi Zhang et al. Journal of Thoracic Oncology
- The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
- (2018) Xiao-Dong Jiao et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis
- (2018) Yuqing Wei et al. LUNG CANCER
- Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas
- (2018) Ying Jin et al. LUNG CANCER
- Short-Term Responders of Non–Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms
- (2018) Yanjun Xu et al. Translational Oncology
- CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis
- (2018) Ye Zhou et al. Clinics and Research in Hepatology and Gastroenterology
- Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
- (2018) Geoffrey R. Oxnard et al. JAMA Oncology
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Mutant p53 as a guardian of the cancer cell
- (2018) Fiamma Mantovani et al. CELL DEATH AND DIFFERENTIATION
- Effect Of Coexisting Kras And Tp53 Mutations In Patients Treated With Chemotherapy For Non-Small Cell Lung Cancer
- (2018) Pascale Tomasini et al. Clinical Lung Cancer
- Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
- (2018) Yan Zhang et al. OncoTargets and Therapy
- Chromatin-remodeling factor, RSF1, controls p53-mediated transcription in apoptosis upon DNA strand breaks
- (2018) Sunwoo Min et al. Cell Death & Disease
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer
- (2017) Emily Castellanos et al. Journal of Thoracic Oncology
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR- Mutated Non–Small Cell Lung Cancer
- (2017) Surein Arulananda et al. Journal of Thoracic Oncology
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
- (2017) A. Oztan et al. LUNG CANCER
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
- (2017) Paul A. VanderLaan et al. LUNG CANCER
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
- (2017) Catherine Labbé et al. LUNG CANCER
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR G796D mutation mediates resistance to osimertinib
- (2017) Di Zheng et al. Oncotarget
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients
- (2016) Yong Won Choi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- P53 and the defenses against genome instability caused by transposons and repetitive elements
- (2016) Arnold J. Levine et al. BIOESSAYS
- Commentary on “Participation of p53 Protein in the Cellular Response to DNA Damage”
- (2016) Michael B. Kastan CANCER RESEARCH
- Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing
- (2016) Andrew L. Paek et al. CELL
- Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
- (2016) Matteo Canale et al. CLINICAL CANCER RESEARCH
- TP53Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response
- (2016) Ge Zhou et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
- (2016) Xiaoli Ma et al. Journal of Thoracic Oncology
- Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
- (2016) Perry Tal et al. Oncotarget
- Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
- (2016) Sun Min Lim et al. Oncotarget
- Genome Stability Requires p53
- (2016) Christine M. Eischen Cold Spring Harbor Perspectives in Medicine
- Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
- (2016) Jianxin Shi et al. PLOS MEDICINE
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Chromothripsis and Kataegis Induced by Telomere Crisis
- (2015) John Maciejowski et al. CELL
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- p53 genes function to restrain mobile elements
- (2015) Annika Wylie et al. GENES & DEVELOPMENT
- Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
- (2015) E. Miyauchi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- p53 in survival, death and metabolic health: a lifeguard with a licence to kill
- (2015) Flore Kruiswijk et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- (2015) Matthew J. Niederst et al. Nature Communications
- Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
- (2015) Emilio Bria et al. Oncotarget
- Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer
- (2014) M. A. Molina-Vila et al. CLINICAL CANCER RESEARCH
- Mutant p53 reactivation by small molecules makes its way to the clinic
- (2014) Vladimir J.N. Bykov et al. FEBS LETTERS
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer
- (2014) Xiaoli Ma et al. Molecular Oncology
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations
- (2013) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial
- (2013) Yuankai Shi et al. LANCET ONCOLOGY
- A Genomics-Based Classification of Human Lung Tumors
- (2013) Science Translational Medicine
- Characterization of the p53 Cistrome – DNA Binding Cooperativity Dissects p53's Tumor Suppressor Functions
- (2013) Katharina Schlereth et al. PLoS Genetics
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations
- (2012) Tobias Rausch et al. CELL
- Distinct p53 genomic binding patterns in normal and cancer-derived human cells
- (2012) Krassimira Botcheva et al. CELL CYCLE
- Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis
- (2012) F Nikulenkov et al. CELL DEATH AND DIFFERENTIATION
- Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort
- (2012) Chiara Scoccianti et al. EUROPEAN RESPIRATORY JOURNAL
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- p53 Dynamics Control Cell Fate
- (2012) J. E. Purvis et al. SCIENCE
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- EGFR Mutations and Lung Cancer
- (2011) Gilda da Cunha Santos et al. Annual Review of Pathology-Mechanisms of Disease
- Field cancerization in the GI tract
- (2011) Trevor A Graham et al. Future Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11
- (2011) J E Noll et al. ONCOGENE
- p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation
- (2011) O. Laptenko et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells
- (2010) Rachel Sarig et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma
- (2010) Takayuki Kosaka et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More